Latest Biopharmaceutical News

Page 1 of 13
An independent interim analysis has confirmed statistically significant iPPS benefits in Paradigm’s rest-of-world knee osteoarthritis cohort, giving the company a possible route to continue development despite the overall trial failing its futility test. Any new trial remains subject to funding, creditor approval and regulatory discussions.
Ada Torres
Ada Torres
19 Nov 2026
Expeditors has outlined a long-term growth model targeting 5% to 7% annual revenue growth and 12% to 15% EPS growth. The logistics group also issued Q4 and full-year 2026 EPS guidance while flagging artificial intelligence, automation and potential acquisitions as part of its growth plan.
Maxwell Dee
Maxwell Dee
19 Nov 2026
Charles River Laboratories will pay about US$470 million in cash for Frontage’s bioanalysis and DMPK operations in Pennsylvania, with a further US$75 million tied to performance. The proposed acquisition expands Charles River’s clinical testing capabilities but will initially be neutral to non-GAAP earnings per share.
Ada Torres
Ada Torres
9 Nov 2026
Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
Victor Sage
30 Oct 2026
Imugene reported an 86% overall response rate in its BTK inhibitor combination cohort, but ended September with only 0.70 quarters of estimated funding at the reported cash burn. The biotechnology company is assessing further capital sources while navigating a leadership transition and convertible note obligations.
Ada Torres
Ada Torres
30 Oct 2026
Paradigm Biopharmaceuticals has secured court approval to delay its second creditors meeting until 27 January 2027, giving administrators more time to resolve outstanding matters. The meeting and administrators’ report could still arrive earlier, potentially within weeks.
Victor Sage
Victor Sage
28 Oct 2026
NeuroScientific Biopharmaceuticals has secured favourable US FDA feedback on its planned StemSmart Phase 2 trial for refractory Crohn’s disease, while appointing a clinical research partner and advancing manufacturing validation. The company enters the next phase with $3.91 million in cash and a targeted trial start by the end of 2026.
Ada Torres
Ada Torres
27 Oct 2026
Paradigm’s administrators have asked the Supreme Court of Western Australia for up to three more months to assess sale and recapitalisation proposals. Without the extension, they say they would have no alternative but to recommend winding up the biotech.
Ada Torres
Ada Torres
23 Oct 2026
CSL has appointed ViiV Healthcare CEO Deborah Waterhouse to lead the biopharmaceutical group from 1 February 2027. Her arrival comes with a substantial UK-pound-denominated remuneration package and a mandate to renew the pipeline while simplifying operations.
Ada Torres
Ada Torres
21 Oct 2026
Paradigm has reported a strong pain and function signal for iPPS outside the US, including a 1.105-point advantage over placebo at Day 112. The result does not revive the halted Phase 3 trial, with the company under administration and a potential funding proposal still unreceived.
Ada Torres
Ada Torres
15 Oct 2026
The US FDA has supported six of seven elements NeuroScientific Biopharmaceuticals put forward for its planned StemSmart Phase 2 Crohn’s disease trial. The remaining issue is a manufacturing control for viral contamination, while trial commencement remains targeted for the end of 2026 and subject to further requirements.
Ada Torres
Ada Torres
13 Oct 2026
Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.
Ada Torres
Ada Torres
30 Sept 2026

Browse the archive

Full archive